MA
REGN icon

MYDA Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

MYDA Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-18,000
Closed -$10.1M – 224
2020
Q3 		$10.1M Sell
18,000
-4,000
-18% -$2.43M 5.23% 2
2020
Q2 		$13.7M Buy
22,000
+16,000
+267% +$9.08M 8.3% 1
2020
Q1 		$2.93M Buy
+6,000
New +$2.47M 1.82% 16

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

MYDA Advisors's REGN Position: Q2 2023 in Review

MYDA Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2023, closing a stake of 2,000 shares — an estimated $1.64M sold.

MYDA Advisors first reported a position in REGN in Q1 2020 and held it in 8 quarters. The position peaked at $6.47M in Q3 2021. 1,165 funds tracked by Wall St. Rank hold REGN as of Q2 2023.

  • MYDA Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • MYDA Advisors sold 2,000 Regeneron Pharmaceuticals shares in Q2 2023, an estimated $1.64M.
  • MYDA Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 8 quarters.
  • MYDA Advisors's Regeneron Pharmaceuticals position peaked at $6.47M in Q3 2021.
  • 1,165 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2023.

Based on MYDA Advisors's 13F filing for Q2 2023, filed 11 Aug 2023.